Pathological Conditions, Anatomical: Clinical Trials

482 trials for Pathological Conditions, Anatomical, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

272 completed, 82 unknown, 37 recruiting, 35 terminated. 482 Phase 3, 93 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3482Completed 272, Unknown 82, Recruiting 37, Terminated 35, Withdrawn 19, Active not recruiting 17, Not yet recruiting 17, Enrolling by invitation 2, Suspended 1
Phase 293Completed 48, Unknown 20, Terminated 7, Recruiting 6, Withdrawn 5, Not yet recruiting 4, Active not recruiting 3

Follow Pathological Conditions, Anatomical: new trials by email Literature Review of Pathological Conditions, Anatomical trials Research Report on Pathological Conditions, Anatomical

Trials (filtered) newest first · largest first

All 482 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.
Minoxidil oral solution, Placebo oral solution - Androgenetic Alopecia, Androgenetic Alopecia (AGA)
Phase 3Not yet recruitingEurofarma Laboratorios S.A.3722027-01-312026-11-06
Clinical Study of DA-002 and DA-005 as a Treatment for Hair Loss
DA-005, Topical minoxidil 5%, DA-002 - Androgenetic Alopecia, Female Pattern Baldness
Phase 3WithdrawnApplied Biology, Inc.2027-01-152026-11-02
Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN)
N1087, Placebo - Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia
Phase 3Not yet recruitingEurofarma Laboratorios S.A.3722027-01-012026-11-04
Efficacy of Botulinum Toxin A Versus Nanofat in the Treatment of Androgenetic Alopecia: A Comparative Clinical Trial
Botulinum Toxin Type A, Autologous Nanofat Injection - Androgenetic Alopecia
Phase 2 / Phase 3Not yet recruitingSherief Ayman Hussein Shaamash402026-12-012026-10-07
Efficacy of Two Brushing Regimens in the Reduction of Established Dental Plaque and Gingivitis
0.412% stannous fluoride toothpaste and flat trimmed toothbrush, 0.76% Na MFP and flat trimmed toothbrush - Plaque, Gingivitis
Phase 3CompletedColgate Palmolive842026-10-092026-11-10
Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia
APSMNF 1, APSMNF 2, Eniagor® - Alopecia, Androgenetic
Phase 3Not yet recruitingApsen Farmaceutica S.A.3362026-10-072026-09-08
NanoSALV vs Standard Topical Care Pathway in Sports-Related Skin Lesions
NanoSALV Catalytic, Standard Topical Care Pathway - Blister of Foot, Blister
Phase 3Not yet recruitingShahab Alizadeh1002026-10-012026-09-08
Clinical Study Examining the Control of Plaque and Gingivitis
Silica Free Meridol, Meridol, Colgate Dental Product - Gingivitis
Phase 3Not yet recruitingColgate Palmolive1352026-10-012026-09-25
A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
GSK5784283, Placebo, Standard of Care - Nasal Polyps
Phase 3RecruitingGlaxoSmithKline2182026-09-282026-11-17
Phase 2/3 Efficacy and Safety of PP405 in Adult Males
PP405 0.05% Topical Gel, Vehicle Topical Gel - Androgenetic Alopecia
Phase 2 / Phase 3RecruitingPelage Pharmaceuticals, Inc.6002026-09-212026-11-19
A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
GSK5784283, Placebo, Standard of Care - Nasal Polyps
Phase 3RecruitingGlaxoSmithKline2182026-09-032026-11-16
Clinical Evaluation of a Toothpaste for Dental Plaque Reduction and Prevention of Gum Problems
0.45% SnF HW with NaF (1450 F), 67% Bicarbonate with NaF (1400 F), Colgate Cavity Protection Toothpaste - Plaque, Dental Plaque
Phase 3RecruitingColgate Palmolive1202026-07-202026-09-25
Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention
Empagliflozin 10 MG, Placebo, Personalized dietary counseling - Kidney Stone, Nephrolithiasis
Phase 3RecruitingInsel Gruppe AG, University Hospital Bern4002026-07-022026-10-23
Baxdrostat and Ventricular Remodeling
Baxdrostat, Placebo - Cardiac Remodeling
Phase 3Not yet recruitingSubodh Verma2862026-06-302026-06-17
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata
Deuruxolitinib, Placebo - Alopecia Areata
Phase 3RecruitingSun Pharma Japan Limited782026-06-192026-10-30
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Donanemab, Placebo - Alzheimer Disease, Dementia
Phase 3RecruitingEli Lilly and Company5502026-05-222026-10-28
Adjuvant Steroid Outcomes in Idiopathic Subglottic Stenosis
Triamcinolone 0.1%, Placebo - Idiopathic Subglottic Stenosis
Phase 3RecruitingJohns Hopkins University2262026-05-202026-11-12
Study to Investigate Toothpaste on Antibacterial Effects in the Different Regions of the Mouth
stannous fluoride toothpaste, 0.76% Sodium Monofluorophosphate (Na MFP) toothpaste - Plaque, Gingivitis
Phase 3CompletedColgate Palmolive952026-05-182026-09-24
Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth
DA-001, Placebo, Phenylephrine - Telogen Effluvium, Female Pattern Hair Loss
Phase 2 / Phase 3Not yet recruitingApplied Biology, Inc.11202026-05-012026-04-13
Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia
Icosapent Ethyl 1000 MG Oral Capsule [Vascepa], Placebo - Inflammation, Community Acquired Pneumonia (CAP)
Phase 3RecruitingOttawa Heart Institute Research Corporation1682026-04-082026-05-11

Showing 20 of 482. Sign in to see all of them.

Narrower conditions

Alopecia (55)  ·  Plaque, Amyloid (47)  ·  Nasal Polyps (34)  ·  Sarcopenia (24)  ·  Intervertebral Disc Displacement (22)  ·  Hernia (21)  ·  Kidney Calculi (20)  ·  Dilatation, Pathologic (19)  ·  Muscular Atrophy (19)  ·  Pelvic Organ Prolapse (19)  ·  Hernia, Inguinal (18)  ·  Hypertrophy, Left Ventricular (18)  ·  Gingivitis (16)  ·  Constriction, Pathologic (15)  ·  Atrophy (14)

Broader conditions

Pathological Conditions, Signs and Symptoms (482)  ·  Signs and Symptoms (99)  ·  Pathologic Processes (88)  ·  Nervous System Diseases (78)  ·  Skin and Connective Tissue Diseases (78)  ·  Neurologic Manifestations (76)  ·  Skin Diseases (69)  ·  Urogenital Diseases (64)  ·  Female Urogenital Diseases and Pregnancy Complications (63)  ·  Hernia (62)  ·  Female Urogenital Diseases (61)  ·  Cardiovascular Diseases (59)  ·  Digestive System Diseases (59)  ·  Hypotrichosis (54)

Interventions

Minoxidil (16)  ·  Bupivacaine (11)  ·  secukinumab (11)  ·  Sodium Chloride (9)  ·  Mometasone Furoate (8)  ·  Saline Solution (8)  ·  Solutions (7)  ·  Standard of Care (7)  ·  Tamsulosin (6)  ·  Atorvastatin (5)  ·  Dutasteride (5)  ·  Lidocaine (5)  ·  Ospemifene (5)  ·  Pregabalin (5)  ·  Riboflavin (5)

Sponsors

Novartis Pharmaceuticals (21)  ·  Colgate Palmolive (13)  ·  GlaxoSmithKline (11)  ·  Assistance Publique - Hôpitaux de Paris (7)  ·  University of Erlangen-Nürnberg Medical School (7)  ·  Pfizer (6)  ·  Eli Lilly and Company (5)  ·  Organon and Co (5)  ·  Shionogi (5)  ·  AstraZeneca (4)  ·  Eisai Inc. (4)  ·  Erasmus Medical Center (4)  ·  Applied Biology, Inc. (3)  ·  Eurofarma Laboratorios S.A. (3)  ·  Hoffmann-La Roche (3)

Countries

United States (184)  ·  Germany (60)  ·  France (59)  ·  Canada (58)  ·  Italy (46)  ·  Spain (45)  ·  United Kingdom (44)  ·  Japan (38)  ·  Poland (36)  ·  China (33)  ·  Netherlands (33)  ·  Belgium (31)  ·  Australia (26)  ·  Russia (26)  ·  Czechia (22)

Top investigators

Wolfgang Kemmler, PhD (4)  ·  Andy Goren, MD (3)  ·  Reid Waldman, M.D. (3)  ·  Timothy Durso, M.D. (3)  ·  Willi A Kalender, PhD (3)  ·  Alessandro Mazzetti, M.D. (2)  ·  Frederik Nevens, MD, PhD (2)  ·  J.F. Lange, professor (2)

Results publications

PMID 33710614, PMID 33548517, PMID 35305260, PMID 37341961, PMID 37951571, PMID 38197558, PMID 41743463, PMID 15933795, PMID 18591942, PMID 25013998, PMID 26507877, PMID 27138015, PMID 27573260, PMID 27576559, PMID 32791950, PMID 33275766, PMID 33345059, PMID 33748660, PMID 34110605, PMID 34289971, PMID 34382434, PMID 36567000, PMID 37214171, PMID 38263353, PMID 38825327, PMID 39356039, PMID 39962358, PMID 40037388, PMID 41461999, PMID 41917311, PMID 42481842, PMID 42823604, PMID 10360498, PMID 11403367, PMID 12172314, PMID 12423712, PMID 12621133, PMID 12719068, PMID 12756590, PMID 12790869, PMID 14598268, PMID 14630977, PMID 14639093, PMID 14700505, PMID 14704728, PMID 14744931, PMID 15107485, PMID 15253184, PMID 15253732, PMID 15647341

NIH funding

2017 (7), 2016 (4), 2015 (3), 2018 (3), 2023 (3), 2008 (2), 2009 (2), 1UG3HL173394-01A1 (1), 2014 (1), 2025 (1), K23HL078901 (1), R01AG021570 (1), R01CA098286 (1), R01DK062030 (1), R01NR004007 (1)